The Coffey Lecture: Steroidogenic enzyme inhibitors and hormone dependent cancer

This publication has 76 references indexed in Scilit:

• Prolonging hormone sensitivity in prostate cancer xenografts through dual inhibition of AR and mTOR
  British Journal of Cancer, 2010
• Trastuzumab Reverses Letrozole Resistance and Amplifies the Sensitivity of Breast Cancer Cells to Estrogen
  Cancer Research, 2009
• Androgen receptor inactivation contributes to antitumor efficacy of 17α-hydroxylase/17,20-lyase inhibitor 3β-hydroxy-17-(1H-benzimidazole-1-yl)androsta-5,16-diene in prostate cancer
  Molecular Cancer Therapeutics, 2008
• A Randomized Trial of Exemestane after Two to Three Years of Tamoxifen Therapy in Postmenopausal Women with Primary Breast Cancer
  New England Journal of Medicine, 2004
• A Randomized Trial of Letrozole in Postmenopausal Women after Five Years of Tamoxifen Therapy for Early-Stage Breast Cancer
  New England Journal of Medicine, 2003
• Phosphorylation of human estrogen receptor α at serine 118 by two distinct signal transduction pathways revealed by phosphorylation-specific antisera
  Oncogene, 2002
• Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial
  The Lancet, 2002
• Androgen Receptor Gene Mutations in Prostate Cancer
  Drugs & Aging, 1997
• A Controlled Trial of Leuprolide with and without Flutamide in Prostatic Carcinoma
  New England Journal of Medicine, 1989
• Concentration of endogenous oestradiol as related to oestradiol receptor sites in breast tumor cytosol
  European Journal of Cancer and Clinical Oncology, 1982